Rezolute to Participate in Upcoming Virtual Healthcare Conferences
August 03, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
Rezolute Added to Russell Microcap® Index
June 28, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
May 27, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to...
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
May 20, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
May 18, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose...
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
May 17, 2021 16:05 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
May 17, 2021 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose...
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
July 27, 2020 08:00 ET
|
Rezolute, Inc.
REDWOOD CITY, California, July 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today provided an update on the status of the Company’s clinical programs in...
Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
June 15, 2020 08:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for...
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
June 10, 2020 08:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), today announced that the company has received rare pediatric disease designation...